Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

JOHNSON & JOHNSON : Credit Suisse reiterates its Buy rating

08/27/2019 | 03:48am EST

In a research note, Credit Suisse analyst Matt Miksic has maintained his recommendation on the stock with a Buy rating.. The target price remains unchanged at USD 156.


© MarketScreener with dpa-AFX Analyser 2019
All news about JOHNSON & JOHNSON
12/01JOHNSON & JOHNSON : European Commission Approves Janssen's TREMFYA®▼ (guse..
PU
12/01JOHNSON & JOHNSON : New Survey Finds Critical Need for Education on Cataracts an..
PR
11/27Covid-19 Vaccine Studies May Suffer as Volunteers Consider Dropping Out
DJ
11/26JOHNSON & JOHNSON : Janssen Pharmaceutical Companies - European Commission Appro..
AQ
11/25JOHNSON & JOHNSON : Pfizer, and Merck Lost $3.5B in Combined YTD Revenue
AQ
11/23JOHNSON & JOHNSON : Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supple..
PU
11/23JOHNSON & JOHNSON : Initiates Second Global Phase 3 Clinical Trial of its Jansse..
PU
11/23JOHNSON & JOHNSON : New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) D..
PU
11/23JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t..
PU
11/23JOHNSON & JOHNSON : Late-Breaking 12-Month Data of Investigational RPGR Gene The..
PU
More news
Financials (USD)
Sales 2020 81 771 M - -
Net income 2020 15 967 M - -
Net Debt 2020 6 543 M - -
P/E ratio 2020 24,3x
Yield 2020 2,69%
Capitalization 388 B 388 B -
EV / Sales 2020 4,83x
EV / Sales 2021 4,37x
Nbr of Employees 132 200
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 164,73 $
Last Close Price 147,45 $
Spread / Highest target 22,1%
Spread / Average Target 11,7%
Spread / Lowest Target -5,73%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.82%388 168
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389
ABBVIE INC.18.12%184 633